Caribou Biosciences (CRBU) Current Deferred Revenue (2020 - 2026)
Caribou Biosciences (CRBU) reported Current Deferred Revenue of $994000.0 for Q1 2026, down 64.86% year-over-year from $2.8 million in Q1 2025, and down 47.55% quarter-over-quarter from $1.9 million in Q4 2025.
Caribou Biosciences (CRBU) Current Deferred Revenue (2020 - 2026) Analysis & Trends
Caribou Biosciences (CRBU) has 7 years of Current Deferred Revenue data on file, last reported at $994000.0 in Q1 2026.
- Current Deferred Revenue for Q1 2026 came in at $994000.0, down 64.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $994000.0 (down 64.86% YoY), and the FY2025 annual result was $1.9 million, down 70.6% from the prior year.
- Current Deferred Revenue declined to $994000.0 in Q1 2026 per CRBU's latest filing, from $1.9 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $27.5 million in Q3 2022 and troughed at $100000.0 in Q1 2022.
- A 5-year average of $8.0 million and a median of $4.6 million in 2025 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2022 and 2024: Current Deferred Revenue jumped 27358.0% in 2022, then slumped 88.6% in 2024.
- A 5-year view of Current Deferred Revenue shows it stood at $9.9 million in 2022, then slipped by 9.94% to $8.9 million in 2023, then declined by 27.97% to $6.4 million in 2024, then tumbled by 70.6% to $1.9 million in 2025, then sank by 47.55% to $994000.0 in 2026.
- Business Quant data shows CRBU's Current Deferred Revenue at $994000.0 in Q1 2026, $1.9 million in Q4 2025, and $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Caribou Biosciences | 177.34 Mn | 59.72 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 994,000.00 |
| Dec 31, 2025 | 1.90 Mn |
| Sep 30, 2025 | 3.97 Mn |
| Jun 30, 2025 | 4.60 Mn |
| Mar 31, 2025 | 2.83 Mn |
| Dec 31, 2024 | 6.45 Mn |
| Sep 30, 2024 | 2.83 Mn |
| Jun 30, 2024 | 2.83 Mn |
| Mar 31, 2024 | 2.83 Mn |
| Dec 31, 2023 | 8.95 Mn |
| Sep 30, 2023 | 9.55 Mn |
| Jun 30, 2023 | 12.96 Mn |
| Mar 31, 2023 | 24.79 Mn |
| Dec 31, 2022 | 9.94 Mn |
| Sep 30, 2022 | 27.46 Mn |
| Jun 30, 2022 | 12.64 Mn |
| Mar 31, 2022 | 100,000.00 |
| Dec 31, 2021 | 30.74 Mn |
| Sep 30, 2021 | 100,000.00 |
| Jun 30, 2021 | 50,000.00 |